Company Overview - Protara Therapeutics Inc (NASDAQ: TARA) was last reviewed in February 2024, when the stock was trading below its cash value, implying a negative valuation for its entire portfolio of drug candidates [1] Investment Approach - The analyst focuses on small-cap companies with high upside potential relative to downside risk, employing a value-based approach while also exploring special and short situations [1] - The analyst is a trained CPA with industry experience, providing a strong foundation for financial analysis [1] Analyst Position - The analyst holds a beneficial long position in TARA shares through stock ownership, options, or other derivatives [2] - The article represents the analyst's personal opinions and is not influenced by compensation or business relationships with the mentioned company [2]
Protara Therapeutics: Rising From The Ashes